Stock 4AB ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights AbbVie Inc. Deutsche Boerse AG

Equities

4AB

US00287Y1091

Market Closed - Deutsche Boerse AG
Other stock markets
 17:18:57 03/07/2024 BST 		5-day change 1st Jan Change
151.6 EUR -4.45% Intraday chart for AbbVie Inc. -5.22% +8.94%
07-03 AbbVie cuts 2024 profit forecast RE
07-01 Merus Names New Chief Medical Officer MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie cuts 2024 profit forecast
RE
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care Stocks Decline in Afternoon Trading
MT
AbbVie: acquisition of Celsius for $250 million
CF
AbbVie Buys Celsius Therapeutics for $250 Million
DJ
AbbVie Buys Celsius Therapeutics for $250 million
MT
AbbVie Buys Celsius Therapeutics for $250 million
MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal
MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment
MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.
CI
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15
MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024
CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. 4AB Stock
  5. News AbbVie Inc.
  6. Highlights